Aprea Therapeutics, Inc. APRE

APRE Company Overview

Aprea Therapeutics, Inc. is a U.S.-based clinical-stage biotechnology company focused on precision oncology and targeted cancer therapies. The company develops small-molecule therapeutics designed to exploit vulnerabilities in cancer cells, particularly through synthetic lethality and DNA damage response pathways. Its research and development activities have centered on oncology indications involving genetically defined tumors, with an emphasis on therapies targeting DNA repair mechanisms and cell-cycle regulation. The company operates within the biotechnology and pharmaceutical research industries and primarily generates value through drug discovery, clinical development, intellectual property, and strategic licensing opportunities rather than commercial product sales.

Aprea Therapeutics was founded in Sweden and later established U.S. operations as part of its transition into a publicly traded oncology-focused biotechnology company. The company previously concentrated on p53 pathway reactivation programs before shifting strategic focus toward next-generation precision oncology assets, including WEE1 kinase inhibition and related synthetic lethality approaches. Its positioning in the market is tied to its specialized oncology pipeline, targeted therapeutic strategy, and focus on biomarker-driven patient populations.